WST vs COO — Key Metrics

Metric WST (WEST PHARMACEUTICAL SERVICES INC) COO (COOPER COMPANIES INC)
Price404.0260.75
Market Cap28.14 Billion11.55 Billion
P/E (TTM)45.0420.66
P/B (Quarterly)9.7791.449
P/S (TTM)8.292.73
Net Profit Margin (TTM)18.813.5
Gross Margin (TTM)37.665.9
ROE (TTM)21.16.9
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

WEST PHARMACEUTICAL SERVICES INC
vs
 
COOPER COMPANIES INC
 
WEST PHARMACEUTICAL SERVICES INC
vs
 
COOPER COMPANIES INC
Performance Comparison
AI Model Recommendation
WST · WEST PHARMACEUTICAL SERVICES INC

Greatly Underperform

-95
UnderperformOutperform
COO · COOPER COMPANIES INC

Underperform

-29
UnderperformOutperform
Recommendation Summary

Stock WST is projected to greatly underperform the market, stock COO is projected to underperform the market. Upfront Recommendation: COO.

Financial Metrics
Prices delayed ~15 min
WST Metrics COO
$404.02 Price $60.75
— Market Capitalization —
45.04 Price to Earnings Ratio 20.66
8.29 Price to Sales 2.73
48.5 Price to FCF Ratio 17.04
22.04 Price to Gross Profit 4.14
372.28 Price to R&D 68.03
15.49 Price to Current Assets 5.06

WST vs COO at a glance

West Pharmaceutical Services INC (WST) and Cooper Companies INC (COO) are both Medical Instruments & Supplies companies in the Healthcare sector. WST is the larger, at $28.1 billion in market value against $11.6 billion for COO, about 2.4 times the size.

On trailing-twelve-month figures, WST trades at 45.0 times trailing earnings and COO at 20.7; net profit margins are 18.8% and 13.5%.

The Upfront Investment model currently rates WST Greatly Underperform and COO Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.